ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Sunday, November 17, 2024

10:30AM-12:30PM: Abstract Number: 1065

A Quality Improvement Project to Improve Contraception Management in Patients with Systemic Lupus Erythematosus on Teratogenic Medications

Measures & Measurement of Healthcare Quality Poster

10:30AM-12:30PM: Abstract Number: 1484

A Retrospective Evaluation of Glucagon-like Peptide-1 Receptor Agonists in SLE Patients

SLE – Diagnosis, Manifestations, & Outcomes Poster II

10:30AM-12:30PM: Abstract Number: 1358

A Step Towards Personalised Medicine – Development and Efficacy of Machine Learning Based Smart-Web Application for Prediction of Steroid Induced Hyperglycemia in Patients with Rheumatoid Arthritis and Other Autoimmune Rheumatic Diseases

RA – Diagnosis, Manifestations, & Outcomes Poster II

10:30AM-12:30PM: Abstract Number: 1041

A Theory of Change for Patient-Initiated Follow-Up Care in Rheumatoid Arthritis

Health Services Research – ACR/ARP Poster II

10:30AM-12:30PM: Abstract Number: 1280

Abnormal Cortical Gyrification Patterns in Adolescents with Childhood-onset SLE: Early Associations with Perceived Fatigue

Pediatric Rheumatology – Clinical Poster II

10:30AM-12:30PM: Abstract Number: 1320

Acceptability and Satisfaction of an Online Resilience-Building Intervention with Peer Health Coaches for Managing Fatigue and Well-Being in Systemic Sclerosis

Psychology/Social Sciences Poster – ARP

10:30AM-12:30PM: Abstract Number: 1031

Access to Advanced Therapies in Axial Spondyloarthritis in Latin America, Data from the PANLAR-ESPALDA Registry

Healthcare Disparities in Rheumatology Poster II

10:30AM-12:30PM: Abstract Number: 1472

Achievement of Low Disease Activity/Remission in Guselkumab-Treated Patients with Moderately-Highly Active Psoriatic Arthritis Regardless of Baseline Characteristics: Pooled Post-Hoc Analysis of Two Phase 3/Randomized Studies

SpA Including PsA – Treatment Poster II

10:30AM-12:30PM: Abstract Number: 1640

ACR/EULAR 2022 Classification Criteria Compared to the ACR 1990 Classification Criteria in the ARTESER Registry of Giant Cell Arteritis

Vasculitis – Non-ANCA-Associated & Related Disorders Poster II

10:30AM-12:30PM: Abstract Number: 0911

Activating B Cells Facilitates the Discovery of Latent Disease-associated Variants

Genetics, Genomics & Proteomics Poster

10:30AM-12:30PM: Abstract Number: 1283

Acute Transverse Myelitis in Pediatric Systemic Lupus Erythematosus

Pediatric Rheumatology – Clinical Poster II

10:30AM-12:30PM: Abstract Number: 1000

Adalimumab Biosimilar-to-biosimilar Switch in Patients with Inflammatory Rheumatic Diseases – Real-world Evidence from the Nationwide Danish Registry, DANBIO

Epidemiology & Public Health Poster II

10:30AM-12:30PM: Abstract Number: 1402

Addressing Unmet Needs in Cannabis and Hemp by Improving Knowledge and Data Collection

Research Methodology Poster – ARP

10:30AM-12:30PM: Abstract Number: 1613

Adherence to Dietary Recommendations and the Risk of Developing Giant Cell Arteritis; A Nested Case-Control Study

Vasculitis – Non-ANCA-Associated & Related Disorders Poster II

10:30AM-12:30PM: Abstract Number: 1259

Adverse Childhood Experiences Are Associated with Patient-Reported Outcomes in Adolescents and Young Adults with Systemic Lupus

Pediatric Rheumatology – Clinical Poster II

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].